Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 142 No. 1314 (2012)

Vasodilator effects of cromakalim and HA 1077 in diabetic rat aorta

  • Tugba Gurpinar
  • Sule Gok
DOI
https://doi.org/10.4414/smw.2012.13558
Cite this as:
Swiss Med Wkly. 2012;142:w13558
Published
25.03.2012

Abstract

BACKGROUND: Impairment of the vasorelaxant responses have been reported in diabetes mellitus. In this study, the roles of the KATP channel and rho kinase pathway were evaluated by using the KATP channel opener cromakalim and Rho-kinase inhibitor HA 1077 in diabetic rat aorta.

METHODS: Adult male Wistar rats weighing (250–300 g) were divided into diabetic and control groups. Diabetes was induced by a single intraperitoneal injection of streptozotocin (STZ, 55 mg/kg/i.p).

RESULTS: Vasodilator responses induced by cromakalim (10–7 to 10–3M) and HA 1077 (10–6 to 10–4M) were significantly less in diabetic rings compared with control rings (p <0.01). The decrease in the relaxant effect of cromakalim was more in endothelium-denuded rings compared to the endothelium-intact rings (p<0.05). There were no significant differences between endothelium intact and non-intact rings in the presence of HA 1077. When two drugs were administered together, relaxation was significantly less than with seperate administration of each drug in the diabetic group (p <0.01). Pre-treatment with N omega-nitro-L-arginine methylester (L-NAME) (10–6 to 10–4M), an NO synthase inhibitor, significantly decreased the relaxant response to cromakalime and HA 1077 in both the control and diabetic groups (p <0.05).

CONCLUSIONS: These results suggest that the impaired relaxant effects were further decreased depending on KATP channel activity but the effects of Rho-kinase enzyme inhibitors on relaxation responses were not significantly changed in diabetes mellitus.

References

  1. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci. 2005;109:143–59.
  2. Lockhart CJ, Hamilton PK, McVeigh KA, McVeigh GE. A cardiologist view of vascular disease in diabetes. Diabetes Obes Metab. 2008;10:279–92.
  3. Xavier FE, Davel AP, Rossoni LV, Vassallo DV. Time-dependent hyperreactivity to phenylephrine in aorta from untreated diabetic rats: role of prostanoids and calcium mobilization. Vascul Pharmacol. 2003;40:67–76.
  4. Brayden JE. Functional roles of KATP channels in vascular smooth muscle. Clin Exp Pharmacol Physiol. 2002;29:312–6.
  5. Standen NB, Quayle JM. K+ channel modulation in arterial smooth muscle. Acta Physiol Scand. 1998;64:549–57.
  6. Strutyns'kyĭ RB, Moĭbenko OO, Pyvovar SM, Dosenko VI, Iahupol's'kyĭ LM. ATP-sensitive potassium channels and changes in their functional activity during streptozocin induced diabetes mellitus. Fiziol Zh. 2003;49:22–30.
  7. Zimmermann PA, Knot HJ, Stevenson AS, Nelson MT. Increased myogenic tone and diminished responsiveness to ATP-sensitive K+ channel openers in cerebral arteries from diabetic rats. Circ Res. 1997;81:996–1004.
  8. Mayhan WG, Faraci FM. Responses of cerebral arterioles in diabetic rats to activation of ATP-sensitive potassium channels. Am J Physiol. 1993;265:152–7.
  9. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev. 2003;83:1325–58.
  10. Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res. 2000;261:44–5.
  11. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990–4.
  12. Shimokawa H. Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci. 2007;28:296–302.
  13. Surma M, Wei L, Shi J. Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol. 2011;7:657–71.
  14. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2011;301:287–96.
  15. Kikuchi Y, Yamada M, Imakiire T, Kushiyama T, Higashi K, Hyodo N, et al. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol. 2007;192:595–603.
  16. Murat N, Soner BC, Demir O, Esen A, Gidener S. Contractility of diabetic human corpus cavernosum smooth muscle in response to serotonin mediated via Rho-kinase. Pharmacology. 2009;84:24–8.
  17. Rikitake Y, Liao JK. Rho-kinase mediates hyperglycemia- induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation. 2005;111:3261–8.
  18. Yao L, Romero MJ, Toque HA, Yang G, Caldwell RB, Caldwell RW. The role of RhoA/Rho kinase pathway in endothelial dysfunction. J Cardiovasc Dis Res. 2010;1:165–70.
  19. Begum N, Sandu OA, Duddy N. Negative regulation of rho signaling by insulin and its impact on actin cytoskeleton organization in vascular smooth muscle cells: role of nitric oxide and cyclic guanosinemonophosphate signaling pathways. Diabetes. 2002;51:2256–63.
  20. Chitaley K, Webb RC. Nitric oxide induces dilation of rat aorta via inhibition of rho-kinase signaling. Hypertension. 2002;39:438–42.
  21. Negi G, Kumar A, Kaundal RK, Gulati A, Sharma SS. Functional and biochemical evidence indicating beneficial effect of Melatonin and Nicotinamide alone and in combination in experimental diabetic neuropathy. Neuropharmacology. 2010;58:585–92.
  22. McCulloch AI, Randall MD. Modulation of vasorelaxant responses to potassium channel openers by basal nitric oxide in the rat isolated superior mesenteric arterial bed. Br J Pharmacol. 1996;117:859–66.
  23. Deka DK, Raviprakash V, Mishra SK. Basal nitric oxide release differentially modulates vasodilations by pinacidil and levcromakalim in goat coronary artery. Eur J Pharmacol. 1998;348:11–23.
  24. Deka DK, Mishra SK, Raviprakash V. L-arginine-induced dilatation of goat coronary artery involves activation of K (ATP) channels. Eur J Pharmacol. 2009;609:113–7.
  25. Kinoshita H, Iwahashi S, Kakutani T, Mizumoto K, Iranami H, Hatano Y. The role of endothelium-derived nitric oxide in relaxations to levcromacalim in the rat aorta. Jpn J Pharm. 1999;81:362–6.
  26. Kishi T, Hirooka Y, Masumoto A, Ito K, Kimura Y, Inokuchi K, et al. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation. 2005;111:2741–7.
  27. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 2005;91:391–2.
  28. Gojo A, Utsunomiya K, Taniguchi K, Yokota T, Ishizawa S, Kanazawa Y, et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2007;568:242–7.
  29. MA Creager, TF Lüscher, F Cosentino, JA Beckman. Diabetes and vascular disease. Pathophysiology, clinical consequences, and medical therapy: part I. Circulation. 2003;108:1527–32.
  30. Shen JZ, Zheng XF. Characteristics of impaired endothelium-dependent relaxation of rat aorta after streptozotocin-induced diabetes. Zhongguo. Yao Li Xue Bao. 1999;20:844–50.
  31. Potenza MA, Gagliardi S, Nacci C, Carratu’ MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem. 2009;16:94–112.
  32. Löhn M, Steioff K, Bleich M, Busch AE, Ivashchenko Y. Inhibition of Rho-kinase stimulates nitric oxide-independent vasorelaxation. Eur J Pharmacol. 2005;179–86.